Akigai Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
Akigai General Information
Description
Developer of a drug development company designed to produce treatments for neuropathic pain. The company maps and markets EGFR inhibitors and development candidates tested in clinical trials, and aims to collaborate with owners to bring an inhibitor to the neuropathic pain market, enabling patients to find relief from chronic pain.
Contact Information
Website
www.akigai.noCorporate Office
- C/o Stig Nordal
- Hasselbakken 7
- 0851 Oslo
- Norway
Corporate Office
- C/o Stig Nordal
- Hasselbakken 7
- 0851 Oslo
- Norway
Akigai Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 01-Jan-2023 | Completed | Pre-Clinical Trials |
Akigai Signals
Akigai Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Startuplab Ventures | Venture Capital | Minority |
Akigai FAQs
-
When was Akigai founded?
Akigai was founded in 2022.
-
Where is Akigai headquartered?
Akigai is headquartered in Oslo, Norway.
-
What is the size of Akigai?
Akigai has 9 total employees.
-
What industry is Akigai in?
Akigai’s primary industry is Drug Discovery.
-
Is Akigai a private or public company?
Akigai is a Private company.
-
What is Akigai’s current revenue?
The current revenue for Akigai is .
-
Who are Akigai’s investors?
Startuplab Ventures has invested in Akigai.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process